Diagnosing cancers of unknown primaries
Friday, 27 February, 2009
A diagnostic test for cancers of unknown primaries developed by scientists from the Peter MacCallum Cancer Centre will be commercialised by Melbourne biotech Circadian Technologies and pathology provider Healthscope.
The diagnostic methodology, co-invented by Peter Mac’s Professor David Bowtell, will be further developed and clinically validated by Clinical Laboratories, a subsidiary of Healthscope.
The test is based comparing the pattern of gene expression of cancers of unknown primaries with a database of known tumours.
Marketing in Australia, New Zealand, Malaysia and Singapore will be handled by Healthscope, while Circadian has rights to the rest of the world.
For more information, see the March/April issue of Australian Life Scientist.
Depression impacts energy at a cellular level, researchers find
Depression symptoms may be rooted in fundamental changes in the way brain and blood cells use...
Are discarded peanut shells the affordable and sustainable path to graphene?
Australian researchers have produced small quantities of high-quality graphene via a new process...
Aussie biotech to manufacture mRNA paediatric brain cancer vaccines
A Queensland-based biotechnology company will manufacture personalised mRNA paediatric brain...
